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Background: Despite the unprecedented and increasing amount of data, relatively
little progress has been made in molecular characterization of mechanisms underlying
Parkinson’s disease. In the area of Parkinson’s research, there is a pressing need to
integrate various pieces of information into a meaningful context of presumed disease
mechanism(s). Disease ontologies provide a novel means for organizing, integrating,
and standardizing the knowledge domains specific to disease in a compact, formalized
and computer-readable form and serve as a reference for knowledge exchange or
systems modeling of disease mechanism.
Methods: The Parkinson’s disease ontology was built according to the life cycle of
ontology building. Structural, functional, and expert evaluation of the ontology was
performed to ensure the quality and usability of the ontology. A novelty metric has
been introduced to measure the gain of new knowledge using the ontology. Finally, a
cause-and-effect model was built around PINK1 and two gene expression studies from
the Gene Expression Omnibus database were re-annotated to demonstrate the
usability of the ontology.
Results: The Parkinson’s disease ontology with a subclass-based taxonomic hierarchy
covers the broad spectrum of major biomedical concepts from molecular to clinical
features of the disease, and also reflects different views on disease features held by
molecular biologists, clinicians and drug developers. The current version of the
ontology contains 632 concepts, which are organized under nine views. The structural
evaluation showed the balanced dispersion of concept classes throughout the
ontology. The functional evaluation demonstrated that the ontology-driven literature
search could gain novel knowledge not present in the reference Parkinson’s knowledge
map. The ontology was able to answer specific questions related to Parkinson’s when
evaluated by experts. Finally, the added value of the Parkinson’s disease ontology is
demonstrated by ontology-driven modeling of PINK1 and re-annotation of gene
expression datasets relevant to Parkinson’s disease.
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Conclusions: Parkinson’s disease ontology delivers the knowledge domain of
Parkinson’s disease in a compact, computer-readable form, which can be further edited
and enriched by the scientific community and also to be used to construct, represent
and automatically extend Parkinson’s-related computable models. A practical version of
the Parkinson’s disease ontology for browsing and editing can be publicly accessed at
http://bioportal.bioontology.org/ontologies/PDON.
Keywords: Parkinson’s disease, ontology, disease modeling, knowledge engineeringBackground
Parkinson’s disease (PD), a progressive movement disorder, is the second most common
neurodegenerative disease [1]. The molecular etiology of sporadic PD has not been resolved
yet and therefore PD is often called an “idiopathic” disease. In recent years, several attempts
at elucidating the molecular etiology of PD have generated large omics data sets [2]. The
emerging systems view on the pathology of neurodegenerative diseases (NDDs) requires an
efficient strategy to aggregate, standardize, represent, and communicate biomedical infor-
mation through controlled vocabularies and ontologies [3]. An ontology is defined as “an
explicit specification of a conceptualization”, which aims to facilitate knowledge sharing [4].
Ontologies are the basis for automated reasoning [5], for large-scale annotation of
entire genomes [6, 7], for data mining in microarray data [8], for prediction of biomo-
lecular interactions [9], and for semantic and ontological search in poorly structured
information sources [10, 11].
A large portfolio of widely accepted and widely used ontologies including Gene Ontology
[7], the Sequence Ontology [12] and the Microarray Gene Expression Database Ontology
[8] has evolved in the life sciences. Gene ontology (GO) is the most frequently used ontol-
ogy in biomedical sciences, which provides standard functional annotations for genes and
gene products. Although GO has facilitated understanding of high-throughput results by
means of enrichment analysis, one of its significant limitations is that it does not capture
domain-specific biological complexity [13]. For example, GO is devoid of any disease-
specific context. It can not be used for answering questions like “which disease subtypes
or syndromes are over-represented in my gene or protein set?” Hence, a more useful GO
ideally should contain: i. disease-specific annotations, ii. disease-specific categories, and iii.
semantics that cover disease knowledge domains.
To include disease-specific biological processes, functionalities, and categories, disease-
specific ontologies that cover a broad spectrum of relevant knowledge are required. Disease
ontologies may reference source terminologies and vocabularies with a hierarchical concept
classification such as the SNOMED CT nomenclature [14], the ICD ontology [15] and the
human disease ontology [16]. These ontologies contain human disease concepts but their
high-level, broad coverage and the lack of depth in these ontologies restrict their usage for
specific disease domains. Malhotra and colleagues addressed this issue in the area of NDDs
by construction of Alzheimer’s disease ontology (ADO) to cover clinical, etiological,
molecular and cellular mechanism aspects of AD [17]. The aim of developing ADO was to
enable semantic mining of patient records and literature for effective retrieval and extrac-
tion of accurate AD-related information, which could be used for modeling disease
processes.
Younesi et al. Theoretical Biology and Medical Modelling  (2015) 12:20 Page 3 of 17Similarly, there is a need for organizing the knowledge domain of PD. In response to this
unmet need, we aimed at creating a disease ontology for PD (PDON) that spans from the
molecular biology of the disease to clinical readouts. PDON has been created with a
subclass-based hierarchy that – for the majority of concepts - uses subsumption relation
(i.e. is_a). However, based on demand from biomedical experts for richer relations, parton-
omy relation (i.e. part_of) was also introduced, as a concession to better usability of the
ontology by interdisciplinary experts. We demonstrate the ontology's usability through our
use cases, keeping in mind that, re-usability by other teams is an important aspect in ontol-
ogy construction and its adoption by the community. As a proof of concept, we performed
evaluation of PDON performance by measuring its ability to recover pre-existing, expert-
curated information from the knowledge space of PD in the literature with the aim of gen-
erating novel insights and hypotheses.
The power of the ontology can be applied to several scenarios, e.g. building recommen-
dation systems by mapping drug failure events to mechanisms and stages of disease/stages
of drug discovery, or distinguishing proven facts from hypotheses and speculations [18].
Furthermore, in the emerging era of systems analysis of NDDs, such a knowledge-driven
approach is expected to support the integration of multiscale and multilevel information
across different biological scales, from molecular networks to clinical readouts.
To this end, we have proposed a model-driven approach to integrating biomedical
knowledge and data into mechanistic models that represent cause-and-effect relationships
among molecular entities, biological processes and their corresponding clinical outcomes.
Using this strategy in the current study, we demonstrate how PDON can be utilized not
only to causally link molecular etiology of PD to impaired biological processes and their
corresponding disease outcome (Application scenario 1) but also to annotate experimen-
tal datasets with their corresponding knowledge description for further integration into
disease models (Application scenario 2).
Results
The purpose of the PDON is to communicate and share the PD knowledge in a standard
form and support text-mining and knowledge discovery. Furthermore, for the construction
of a large, integrative knowledge base on neurodegenerative diseases, PDON can be used
for metadata annotation of various omics data sets available in the public domain. The
PDON encompasses clinical and non-clinical aspects of PD and is expected to support
retrieval of information on syndromes, etiology, treatment, experimental models, diagnosis
and symptoms of PD (Fig. 1).
PDON represents a range of key concepts specific to the knowledge domain of
Parkinson’s disease through different views, which have been integrated in the ontol-
ogy. Views are root super-classes that organize concepts within a certain knowledge
domain, as they are realized and seen by experts in reality. PDON is represented by
nine views:
The view ‘Clinical aspects’ describes a broad range of motor and non-motor features
displayed by PD patients. These features have been classified into three upper-level cat-
egories that capture clinical concepts related to “diagnostics”, “symptomatology” and
“treatment” of PD.
The view ‘Etiology’ captures both genetic and environmental factors that are known to
cause familiar PD and Parkinsonism due to toxic dopaminergic cell death, respectively.
Fig. 1 Upper-level classes of PDON as represented in the Protégé ontology editor software. Super-classes
represent different biological views (perspectives) suggested by experts under which PD-specific knowledge
is modeled
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addition, epidemiologically confirmed factors such as smoking and pesticides have been
also included.
The view ‘Model of Parkinson’s disease’ contains various in-vivo and in-vitro disease
models that are in routine use in PD research.
The view ‘Neuropathology’ was included to highlight two prototypic hypotheses of PD-
related mechanisms, namely synucleopathy and the emerging tauopathy. It is expected
that this view is populated further and enriched with more neuropathological concepts by
the PD research community.
The view ‘Familial neurodegenerative disease’ includes those hereditary disorders that
are clinically associated with PD, such as Huntington’s and Wilson’s diseases.
‘Idiopathic Parkinson’s disease’, ‘Primary parkinsonism’, ‘Secondary parkinsonism’, and
‘Parkinson-plus Syndrome’ represent four separate views as per recommendation of the
clinical expert panel. These views provide a categorized overview on distinct syndromes
associated with PD based on their origin of cause. For example, the primary parkinson-
ism class represents parkinsonian syndromes for which a definite cause has been identi-
fied (e.g. mutations in PARK genes), whereas secondary parkinsonism syndromes are
induced by a hypothetical cause that is potentially identifiable. Those syndromes with
unknown causative factor have been clinically assigned to the Parkinson-plus view.
In PDON, each concept class is supported by a scientific definition, a valid scientific
reference (if available) and existing synonyms (Fig. 2). Definitions have been selected from
review papers, journal articles and handbooks with consideration of the consensus defini-
tions accepted in the PD research community. It is noteworthy that the PDON is expected
to grow over time by inclusion of missing or emerging concepts. Due to dynamic research
in the PD field, the structure of ontology is subject to change. We do explicitly invite
experts in the field to critically review, revise and optimize the draft ontology presented in
this manuscript. The ontology will be updated based on the feedback collected from
experts, which includes concept edition, re-defining concepts with missing or insufficient
explanation, or new relationship proposal. This is accomplished through the possibility of
adding comments or proposals to the ontology’s webpage on the BioPortal repository. The
Bioinformatics group at Fraunhofer Institute SCAI that owns the ontology collects these
feedbacks and manages the updated releases. The ontology can be freely accessed and
downloaded at http://www.scai.fraunhofer.de/en/business-research-areas/bioinformatics/
downloads.html.
Fig. 2 A snapshot of the annotation field for PDON concepts as presented in the Protégé ontology editor.
Each PDON concept has been annotated with definition, reference, and synonyms
Younesi et al. Theoretical Biology and Medical Modelling  (2015) 12:20 Page 5 of 17Structural evaluation:
PDON was evaluated for structural features reflecting its topology and logical proper-
ties. The high-level semantic framework of PDON contains nine super-classes, followed
by sub-classes that specifically capture the sub-domain knowledge of PD. PDON was
characterized for its structural features using parameters that have been summarized in
Table 1. As shown in Table 1, PDON covers the knowledge domain of PD using 632
concept classes for which a high number of synonyms has been collected. The depth
and width of the ontology reflect sufficient coverage of the PD knowledge domain with
a reasonable distribution of concepts at various levels. The so-called Fanout-ness factor
represents distribution of concepts over the entire ontology structure; its comparably
high value is indicative of the balanced dispersion of concept classes throughout the
ontology with consistent, broad representation of the knowledge domain across ontol-
ogy branches.
Functional evaluation and gain of knowledge measurement:
The model-based evaluation approach proposed in this work requires that a list of
genes and proteins associated to all aspects of PD is being captured by PDON and
assessed against the PD disease map as a widely accepted reference (see Evaluation
section). Obviously, there is the need to expand the PDON to both coding and
non-coding RNA, lipids and eventually to non-coding DNA and modification
thereof as well. Since the knowledge space of PD is vast, PDON-driven faceted
search enables us to distinguish between the core knowledge directly linked to PD
pathophysiology and the emerging novel knowledge surrounding PD pathophysi-
ology (e.g. observations through animal models or epidemiological data). For this
purpose, separate queries were performed in the SCAIView environment (accessed
on 28.04.2014):
1. a query with all the PDON concepts, which resulted in a list of 16333 human
genes/proteins; and
Table 1 Summary of the structural parameters and their corresponding values measured for PDON
Features No. of classes No. of synonyms Max. depth Depth variance Avg. width Fanout-ness
PDON 631 505 8 1.74 78.8 0.81
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CONCEPT>”]) AND [MeSH Disease:”Parkinson Disease”] AND [Free Text:” < THE
BRANCH NAME>”]
661 human-specific genes/proteins could be extracted from the PD map (i.e. gold stand-
ard), which were used for benchmarking the functional performance of the PDON. For
this purpose, three branches of the PDON (Etiology, Clinical aspects, Neuropathology)
were used to query PubMed abstracts in SCAIView as formulated above (see Methods).
Manual curation of the total number of retrieved documents per branch (NTM) led to the
identification of those genes/proteins that are relevant to the context of the searched
branch (TM). Table 2 summarizes these results and shows calculation of the knowledge
gain (i.e. the information gained with the support of ontology from text mining in addition
to the information already existed in the gold standard, based on the formula described in
the Methods section for the knowledge gain calculation) as well as enriched pathways for
the gained knowledge to represent the content of this new knowledge. Accordingly, these
results demonstrate that PDON-assisted search not only retrieved the majority of proteins
already embedded in the PD map gold standard but also captured a large portion of the
PD knowledge domain, which has not been represented in the PD disease map so far (gain
of novel knowledge from the literature). The rest of genes/proteins that were retrieved by
these PDON-driven queries but not found in the PD model represents additional
potential knowledge gained from the literature relevant to PD. This new knowledge can
be used after expert curation to extend or enrich the current PD disease map and thus, it
is important to measure the added value of the potentially novel gained knowledge
through the metric that was introduced in the Methods section.
Table 2 lists parameters of the knowledge gain metric and corresponding novel pathways
for selected views of the PDON. The highest percentage of new knowledge by PDON is
gained in the branches representing neuropathology, etiology and clinical concepts, respect-
ively. Functional analysis of these additionally identified genes/proteins shows that a coupleTable 2 Parameter values and the final value of the knowledge gain calculated for three major
branches of PDON. TM: number of relevant genes/proteins to the branch by PDON; GS: number of
genes/proteins extracted from the PD map as gold standard; N: total number of genes/proteins for
each branch retrieved by PDON. The queries were performed on Human Genes/Proteins and
SCAIView returned lists of unique genes specific to each branch. Numbers represent counts of




TM TM ∩ GS NTM Gain of novel
knowledge
Enriched pathways in the content of new
knowledge




286 97 683 27 % GPCR signaling, Neuroactive ligand-receptor
interactions, Rhodopsin-like receptors, Peptide
ligand-binding receptors, Gastrin-CREB signaling
Neuropathology
of PD
252 91 471 34 % Immune system, Signaling by GPCR, Endocytosis,
Toll-like receptor signaling, Hemostasis
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be added to the existing PD map.Expert evaluation:
PDON-driven information retrieval and extraction can guide analysis of literature in
answering complex scientific questions. Experts in the knowledge domain of PD were
asked to design complex questions highly relevant for their research work to be posed to
the ontology. We selected 2 of these questions that contained concepts specific to the
PDON and benchmarked the performance of PDON against PubMed by retrieving litera-
ture abstracts that contained hypotheses answering these competency questions. Table 3
provides an overview on the number of total hits as well as the number of relevant docu-
ments that were manually verified to contain a hypothetical answer to the corresponding
question. Analyses were performed using both SCAIView and PubMed (see Table 3). The
following queries were formulated based on the competency questions and were posed to
SCAIView and PubMed retrieval systems:Competency question 1. Return all literature references mentioning drugs used to treat
'freezing' in PD.
Query in SCAIView: [MeSH Disease:"Parkinson Disease"] AND [Parkinson
Ontology:"Freezing"] AND [Parkinson Ontology:“Gait disturbance“]) AND
[ATC:"ANTI-PARKINSON DRUGS"]) AND [Free Text:“therapy“]
Query in PubMed: (("parkinson disease"[MeSH Terms] AND gait[Text Word]) AND
freezing[Text Word]) AND drug[Text Word])) AND therapy[Text Word]Competency question 2. Return literature references containing genes that provide
resistance to PD in the animal model MPTP.
Query in SCAIView: [MeSH Disease:"Parkinson Disease"] AND [Full Text:"resistance"]
AND [Parkinson Ontology:"MPTP model"]) AND [Mouse Genes/Proteins]
Query in PubMed: (((parkinson disease[MeSH Terms]) AND mptp[MeSH Terms])
AND resistance[Text Word]) AND animal model[MeSH Terms]
The PDON-driven semantic search in SCAIView was also able to provide the precise
answer to all competency questions by listing drug names (competency question 1),Table 3 Results of PDON evaluation based on expert questions. For both competency questions,
PDON-driven search in SCAIView retrieved less number of abstracts than simple queries in PubMed
but more relevant to the questions (i.e. less noise). This performance efficiency for the PDON-driven























retrieval - % PubMed
retrieval)
1 70 20 95 20 28.7 %-21 %: 7.7 %
2 6 5 3 1 83.3 %-33.3 %: 50 %
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ies do not return lists of named entities, we could not compare the performance at the
entity level.
As the results of benchmarking indicate in Table 3 as well, PDON-driven search outper-
forms PubMed when it comes to specificity (i.e. less noise in terms of the number of
retrieved documents) and coverage (i.e. higher number of relevant documents). For less
specific queries, PDON performs at the level of PubMed baseline or better. When com-
pared to PubMed, PDON showed higher performance (greater specificity) in retrieving
relevant document, i.e. documents containing appropriate answers in the form of hypoth-
eses related to the expert question.Application scenario 1: linking etiology view of the PDON to cause-and-effect mechanistic
models
One of the biggest scientific challenges we face in the area of NDDs such as AD or PD is
the lack of a clear understanding of the alterations at the molecular level that leads to
disease manifestation and the very cause of those alterations. As a consequence, the
molecular etiology of neither AD nor PD can be described in a formal knowledge repre-
sentation. In a recent “comment” in Nature Reviews Drug Discovery, Ismael Kola and
John Bell called for a new approach towards classifying diseases [19]. They proposed a
new taxonomy of disease based on the (presumed) underlying mechanisms. The under-
lying fundamental notion is that any personalization of treatment requires a deep under-
standing of the pathophysiological mechanisms and - as a consequence – should be based
on a mechanistic understanding of disease etiology.Table 4 Results of PDON-driven search in response to expert competency questions. In contrast to
PubMed queries, PDON-driven search in SCAIView generated a list of entities that precisely answer
the competency questions
Competency question Entities PubMed ID
Return all literature references mentioning drugs used














Return literature references containing genes that provide resistance
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knowledge in the knowledge representation describing PD. Although this is not yet
the “mechanism-based taxonomy” that Kola and Bell called for, it may represent a
first step towards integrating mechanistic information on PD – as far as this informa-
tion can be represented by means of causal and correlative relationships. A dedicated
modeling syntax for the representation of causal and correlative relationships is pro-
vided by the Biological Language Expression, OpenBEL [20]. OpenBEL is ideally
suited to capture knowledge on causal and correlative relationships that may exist at
any level of biomedicine. The OpenBEL language can be used for multi-scale and
multi-level modeling of any chain of events that may underlie disease.
In the “etiology” section of the PDON, we have encoded those PD-specific disease pro-
cesses that are comparably well understood in OpenBEL and included these representations
directly as “small models” in the PDON. These models can be easily extended, automatically
enriched and extracted from the PDON. To exemplify this approach, we have chosen
“inherited familial case of PD”, which provides a straightforward scenario for “cause-effect”
relationships.
A substantial amount of information on the cause (the mutation) and the conse-
quences (at cellular or organ level) is available for parkinsonism. To demonstrate
how this information can be transformed into a cause-and-effect model, we used
PDON to retrieve mutation information of PINK1. PTEN-induced putative kinase 1
(PINK1) is a mitochondrial serine/threonine-protein kinase encoded by the PINK1
gene and is thought to protect cells from stress-induced mitochondrial dysfunction.
Fig. 3 illustrates such a model for pathologic mechanism associated to mutations in
PINK1. This model explains how a number of polymorphisms in PINK1 gene antagonize
the protective effects of PINK1 by exerting a causal effect on downstream biological
processes such as increased response to oxidative stress leading to increased apoptosis,
increased molecular activity of CASP3, and negative effect on cellular respiration and
bioenergetics in mitochondria. The CASP3 protein is a member of the cysteine-aspartic
acid protease (caspase) family and its activation leads to the execution of cell apoptosis.
Moreover, the model uncovers the causal effect of PINK1 variants on increased transloca-
tion of the CYC1 protein to mitochondrial membranes, which has been shown to result
in cell death in neurons [21].
Altogether, this model illustrates the chain of cause-and-effect events (“chain of caus-
ation”) starting from the causal effect of defined mutations on cellular processes and ending
in clinical manifestations of disease outcomes.Application scenario 2: Re-annotation of gene expression data sets with the PDON
concept classes
One of the obvious benefits of disease ontologies is their ability to harmonise the annota-
tion of data sets with well-curated terms in their controlled vocabularies. Consistently
annotated gene expression data sets will facilitate the automated identification of compar-
able studies in systematic meta-analyses that aim to identify patterns of expression or
interesting relationships between expressed genes that may come to light in the context of
multiple studies. Gene expression studies can be found in the GEO (Gene Expression
Omnibus) database, which is publicly available [22]. To demonstrate the use of PDON for
Fig. 3 Network visualization of the BEL mechanistic model for causal mutations in PINK1. The model
represents the causal association of upstream variants of PINK1 (highlighted in yellow) with downstream
pathways and biological processes (highlighted in red). Genes are shown in cyan, intermediary processes in
blue, translocation in grey, and reactive oxygen species in green. Relationships have been represented as
increase (delta-shaped arrows), decrease (T-shaped arrows), association (diamond-shaped arrows) or
variation (circle-shaped arrows). Direct effects have been shown by ‘increase’ or ‘decrease’ annotations on
edges whereas indirect effects with unknown intermediate steps are represented by ‘association’ and
‘positive/negative correlation’ relations. Moreover, activation effect of one molecule on another is shown
with ‘acts in’, translocation process is annotated with ‘translocates’, and phosphorylation processes have
been represented by ‘has_Modification’
Younesi et al. Theoretical Biology and Medical Modelling  (2015) 12:20 Page 10 of 17the re-annotation of gene expression data sets we have selected from the GEO database
two examples for gene expression data sets with rather heterogeneous annotations:
GSE 16658 ; as an example of a data set with rather limited annotation
GSE 32037 ; as an example of a GEO data set with comparably rich annotation
The rich annotation of GSE 32037 becomes obvious, when the “description field” of this
GEO entry is subjected to a text-mining pipeline that identifies PDON terms in text
(Fig. 4). In contrast, the description field of the GSE 16658 data set is rather limited with
respect to information content (Fig. 5).
The observed lack of detail in the description of gene expression data fields is a common
phenomenon with many primary data repositories; ArrayExpress – a database for functional
genomics experiments including gene expression studies [23]- therefore is systematically re-
annotating all data sets, but that is a manual process done by expert curators who usually
follow annotation guidelines that are valid for a broad spectrum of indication areas and thus
do not represent specific information at great detail.
More detailed information about the cohort of patients is, however, often available
from the primary publication describing the data set. In our example, the respective
data set has been described in a publication that is available as open access. The terms
and conditions of the journal do allow automated analysis of the full text. Therefore,
the complete full text publication describing GSE 16658 was subjected to automated
analysis with PDON terms [24].
The complete full text publication describing GSE 16658 was subjected to automated
analysis with terms from the PDON terminology using a UIMA-based annotation workflow.
Unstructured Information Management Architecture (UIMA) is content analytics software,
Fig. 4 Rich annotation of the description field for the GSE 32037 entry in the GEO database using PDON
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biomedical publications [25]. Detailed information on the patient cohort underlying the
study is tagged and indicated by mark-ups (Additional file 1). Moreover, the ubiquitin path-
way, which has been identified as a pathogenic pathway in this publication, was highlighted
by PDON repeatedly. As demonstrated in this example, curation teams can readily make
use of automatically pre-annotated text to enrich the annotation of GSE 16658 with the
PDON terminology.Discussion
Disease-specific ontologies are emerging as powerful semantic tools, which go
beyond the scope of GO and offer high semantic specificity and sensitivity by placing
the disease context at the center. This trend is indicative of the fact that successful
development of novel biomarkers and drugs requires an integrated systems view of
the pathophysiological mechanisms that underlie disease, which is highly geared
towards understanding connections across multiple biological scales, from molecular
interactions to disease phenotypes. Among chronic and complex diseases, NDDs are
the most challenging diseases to deal with and present a high level of heterogeneity
ranging from diverse molecular mechanisms, various cell types and anatomical
regions to different levels of clinical manifestation. Thus, harmonization of such highFig. 5 Limited annotation information in a relevant gene expression data set. The description of GSE 16658
states the purpose of the study and provides some information on the type of cells (PBMCs) used for the
isolation of patient samples
Younesi et al. Theoretical Biology and Medical Modelling  (2015) 12:20 Page 12 of 17diversity at the data level and enormous heterogeneity at the clinical level needs
high-resolution representation of the knowledge domains specific to NDDs.
In the field of NDDs disease-specific ontologies such as epilepsy ontology [26] and
Alzheimer’s disease ontology [17] have been recently introduced. However, most potential
users of such ontologies including molecular biologists and clinicians find the notations of
such formal representations counter-intuitive and non-reusable. PDON not only provides
a standard terminology and platform for interoperability of the PD knowledge domain
among research groups, but also supports users via literature search through its lexica-
lized form. The broad coverage of PD-specific concepts at various granularity levels
ensures that PDON enables users to capture and integrate PD-related information for
systems analysis purposes. In terms of specificity of the PDON search, we found that the
maximum overlap of the PDON-derived gene list with the PD map-derived genes is
reached in each query within the top 50 genes returned by SCAIView and the most inter-
esting genes missing in the PD model were then identified after this rank position. The
PDON search covered more than 90 % of the gold standard entity list from the PD map
reference when the entire knowledge domain of PD was queried, which shows the high
sensitivity of the PDON. However, the low gene overlap between the gold standard (the
reference PD map) and the PDON-derived list of genes (Table 2) is indicative of the large
amount of peripheral information that has been used in the construction of the PD dis-
ease map complementary to the core pathology. For instance, among the novel knowledge
gained by PDON is ATP5I protein, which is a part of the ATP synthase complex in the
mitochondrial ROS cascade and complements the core cascades involved in mitochon-
drial dysfunction under PD condition. In the reference PD map, however, this protein has
not been shown and only complex V has been presented. On the other hand, this com-
parison suggests that PDON-derived results contain rich information content relevant to
the core pathophysiology of PD, which is still absent in the PD disease map and can be
potentially included in the next version. Introduction of the gain of knowledge measure-
ment metric made it possible to quantitatively measure the gain of novel information con-
tent captured by PDON. Moreover, representation of the gained knowledge by enriched
pathways confirms the novelty of the gained knowledge in comparison to the reference
PD map, as these pathways are not present in the current reference PD map.
An important feature of the PDON is its capacity to project multiple perspectives of the
PD knowledge domain among stakeholders in both academia and industry from molecu-
lar biology to epidemiological and clinical studies. For instance, during the construction
and separate rounds of curation with both clinicians and molecular biologists, special
attention was paid to bridging the gap between two higher-level perspectives, namely the
perspective of clinicians and the perspective of drug developers. Due to the representation
of different perspectives in the domain of PD research, we do hope that the PDON will be
broadly adopted and used for the exchange of data, annotation of existing data sets and
the communication of knowledge.
The unique value that application of PDON can provide to the PD research community
was demonstrated by using PDON for the rapid construction of mechanistic BEL models.
This ability can be used for representation as well as visualization of the PD knowledge
subdomains in the form of cause-and-effect systems models. As demonstrated in the ap-
plication scenario, mutations in the PINK1 gene is well known for their causal association
to familial early onset PD but their mechanistic model reveals their potential involvement
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be used for investigating associations between familial and sporadic PD in general, and
associations between parkinsonism syndromes in particular at the mechanism level. To
this end, the authors foresee that one potential application of PDON could be revision of
the current classification of PD syndromes based on etiological mechanism underlying
each syndrome.Conclusions
In the times of re-orientating PD research towards systems modeling and analysis, the
Parkinson’s disease ontology serves as a semantic framework for standardization and
harmonization of a large amount of heterogeneous data and knowledge in the field of PD.
Indeed, PDON delivers the knowledge domain of PD in a compact, computer-readable
form, which can be further used to construct, represent and automatically extend PD-
related computable models. Beside advantages, PDON has its own limitations such as
missing concepts, lack of standard definitions, or incompleteness of synonym list.
Addressing these shortcomings requires constant contribution of the PD research com-
munity to the betterment of the current version of PDON.Methods
The PDON has been constructed in accordance to the ontology-building life cycle [27].
Such a methodology – compared to other methods - offers a set of defined stages when
building ontologies to assist identifying construction principles for each stage as well as
relationships among stages.Knowledge acquisition and conceptualization
A first collection of terms and concepts related to PD was generated by scanning various
knowledge sources. Initially we used a list of sources recommended by Parkinson’s experts
(i.e. neuroscientists and clinicians) including medical text books such as Parkinson’s Disease
and Movement Disorders [28] and encyclopedias like Encyclopedia of Parkinson’s Disease
[29]. After extracting the key concepts manually, we then used the search functionality of
Google (such as Books and Scholar) to find online resources that contain additional
concepts describing the knowledge domain of PD (e.g. www.parkinsons.org). Other
resources including review articles and content of online books were used in this way and
any available hierarchical organization (structure) of the concepts was extracted along with
the concepts themselves. Corresponding definitions and references were also included.
Concept enrichment was assisted by n-gram analysis so that publication abstracts were
scanned for 2-grams to 5-grams, describing meaningful terms with 2 to 5 words, by using a
java program written for this purpose. These n-grams underwent manual inspection and
relevant terms were added to the ontology.Formal representation
The Protégé OWL editor was used as a tool for building the PDON in Web Ontology
Language (OWL) format [30]. Concept classes were further annotated with synonyms.
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Structural features of the ontology were computed using an existing java script [31]. These
features include topological and logic properties such as: depth and breadth (related to
the cardinality of paths in a graph), tangledness (related to multi-hierarchical nodes), and
fan-outness (related to the dispersion of nodes).Functional evaluation
Functional performance of the ontology was measured through a novel model-based
evaluation approach. In this approach, the assumption is that the expert-curated molecular
map of PD, which has been recently published by Fujita et al. (2013), represents a good
part of the current knowledge about molecular processes related to PD and is considered
as the gold standard [32]. A list of genes and proteins in this map was used for bench-
marking the list of genes and proteins that had been retrieved from the literature through
PDON-supported literature mining.Expert evaluation
The expert panel’s revision of the ontological structure is considered as a genuine evalu-
ation for disease ontologies [33]. Revisions of the PDON drafts were initially performed in
the presence of an expert panel of 6 experts in PD from UCB Pharma, composed of
molecular biologists, clinicians and physicians, who generated the “pharma view” of the
ontology. In order to generate the “clinical view” of the ontology, the PDON underwent a
manual curation by clinician experts in the field of PD (UW and DS).Ontology-driven information retrieval and extraction
Transformation of the ontology OWL format into a dictionary file was achieved using a
Java program that extracts the concept names and the corresponding synonyms from the
ontology OWL structure and assigns unique identifiers to each concept which can be
stored in form of a dictionary. This dictionary was incorporated into the text-mining tool
ProMiner [34] and results were deployed in the semantic search engine SCAIView for
context-sensitive visualization of query results. SCAIView is a semantic search engine that
provides a text mining-based environment for information retrieval and extraction from
PubMed publications using various terminologies and ontologies [35]. SCAIView environ-
ment can be freely accessed under http://www.scaiview.com/scaiview-academia.html;
PubMed portal can be accessed through http://www.ncbi.nlm.nih.gov/pubmed.Fig. 6 Overview of the overall workflow used for construction of mechanistic BEL models
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Current disease models often suffer from the limited information content and are usually
representative of the well-established knowledge at the core of disease knowledge domain.
Application of ontology-driven information retrieval technology helps to extend the core
knowledge domain to its boundaries by automated capturing of novel biological entities
(here: genes/proteins) that represent the less established or emerging knowledge (gain of
novel knowledge). We introduce a metric for the measurement of novel complementary
knowledge using the following formula:
Novelty LTM׀LGSð Þ ¼ TMj j − TM ∩ GSj jð Þ =NTM
Where:LTM = the “curated” result list from text-mining (TM) algorithm
LGS = the result list from the reference gold standard
NTM = the total number of entities retrieved from TM
TM: Relevant (true positive) entities (i.e. genes/proteins)
GS: Gold standard list of entities
TM ∩ GS: Overlap between entities retrieved by TM and entities extracted from GS
To show the biological content of the novel knowledge gain by this approach, the list
of novel genes/proteins retrieved by PDON (i.e. |TM| - |TM ∩ GS|) was subjected to
the pathway enrichment analysis using MsigDB [36].
Mechanistic model building
Around PINK1 gene, which is involved in the pathology of familial PD, a “pathophysiology
mechanism” model was built based on OpenBEL, a modeling language ideally suited to rep-
resent causal and correlative relationships. PDON was used in the SCAIView environment
to formulate the following query for PINK1 mutations:
(([SNPs]) AND [Human Genes/Proteins:”PINK1”]) AND [PDON]
Retrieved abstracts were checked manually for the relevance of their information
content and then subjected to the process of BEL coding by manual extraction of the <
subject – relationship – object > predicates and converting them into the BEL script in
the BEL-editor software [37]. These scripts were converted into network models with
functionality of the BEL-editor and visualized by the Cytoscape software [38]. The over-
all workflow of mechanistic model building has been illustrated in Fig. 6.
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